In vivo use of A-443654 was previously reported in mice, and when delivered by subcutaneous injection, it reached plasma and tissue concentrations above 0.5 μM and effectively inhibited mTOR phosphorylation in human prostate tumor xenografts (22). Here, MTOR is linked to prostate neoplasm.